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Abstract
Background: In breast cancer, the HER2/neu oncoprotein, which belongs to the epidermal growth factor receptor
family, may trigger activation of the phosphoinositide-3 kinase (PI3K)/Akt pathway, which controls cell proliferation,
survival, migration, and invasion. In this study, we examined the question of whether or not adenine nucleotide
translocase 2 (ANT2) short hairpin RNA (shRNA)-mediated down-regulation of HER2/neu and inhibitory effects on
the PI3K/Akt signaling pathway suppressed migration and invasiveness of breast cancer cells.
Methods: We utilized an ANT2 vector-based RNA interference approach to inhibition of ANT2 expression, and the
HER2/neu-overexpressing human breast cancer cell line, SK-BR3, was used throughout the study.
Results: In this study, ANT2 shRNA decreased HER2/neu protein levels by promoting degradation of HER2/neu
protein through dissociation from heat shock protein 90 (HSP90). As a result, ANT2 shRNA induced inhibitory
effects on the PI3K/Akt signaling pathway. Inhibition of PI3K/Akt signaling by ANT2 shRNA caused down-regulation
of membrane-type 1 matrix metalloproteinase (MT1-MMP) and vascular endothelial growth factor (VEGF)
expression, decreased matrix metalloproteinase 2 (MMP2) and MMP9 activity, and suppressed migration and
invasion of breast cancer cells.
Conclusions: These results indicate that knock-down of ANT2 by shRNA down-regulates HER2/neu through
suppression of HSP90’s function and inhibits the PI3K/Akt signaling pathway, resulting ultimately in suppressed
migration and invasion of breast cancer cells.
Background
Breast cancer is the most common cancer among
w o m e ni nt h ew e s t e r nw o r l da n dt h es e c o n dl e a d i n g
cause of cancer related death in women [1]. Gene ampli-
fication and/or overexpression of some oncogenes have
been implicated in development and progression of
breast cancers. HER2/neu (also known as ErbB2) is one
of the best characterized oncogenes linked with poor
prognosis of breast cancer [2]. Overexpression of HER2/
neu is found in about 30% of human breast cancers and
correlates with more aggressive tumors and greater
resistance to cancer chemotherapy [3].
The HER2/neu oncoprotein is a transmembrane
receptor, belonging to the epidermal growth factor
receptor family, with tyrosine kinase activity, resulting
in intracellular signaling and activation of genes
involved in cell growth, which is associated with shor-
tened survival, enhanced aggressiveness, and other poor
prognostic factors in breast cancer [4]. Activation of
HER2/neu may trigger activation of downstream signal-
ing pathways, such as the phosphoinositide-3 kinase
(PI3K)/Akt pathway, which, controls cell proliferation,
survival, migration, and invasion [5]. Studies performed
in animal models have shown that down regulation of
HER2/neu by repression of the HER2/neu promoter or
by use of anti-HER2/neu antibodies can suppress tumor
growth and dissemination. One therapeutic approach
that has already reached clinical application is the use
of an unarmed monoclonal antibody known as Trastu-
zumab (Herceptin™). Studies have attributed the thera-
peutic potential of anti-HER2/neu antibodies to their
ability to enhance intracellular degradation of the cell
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that manipulation of HER2/neu may be of substantial
value in treatment of breast cancer [6-12].
Heat shock protein 90 (HSP90) is known as a chaper-
one, assisting in correct folding of nascent proteins
including many kinds of oncoproteins, and therefore is
associated with tumor growth. Suppression of HSP90
reveals down regulation of its client proteins including
Raf-1, Erk, Pdk-1, Akt, and HER2/neu [13-15]. ATP
binding at the N-terminal domain of HSP90 is indispen-
sable for the appropriate activity of HSP90 [16,17].
Adenine nucleotide translocase 2 (ANT2), abundantly
located in the inner mitochondrial membrane, partici-
pates in the formation of mitochondrial permeability
transition pore complex, and also plays an important
role in the cellular energy metabolism by catalyzing the
exchange of mitochondrial ATP for cytosolic ADP and
thereby influencing mitochondrial oxidative phosphory-
lation [18]. In fact, ANT2 suppression by a DNA vector
based RNA interference approach expressing short hair-
pin RNA (shRNA) resulted ATP depletion from breast
cancer cells and induced cell death [19]. We therefore
hypothesized that HSP90 might be one of the main tar-
gets which functions are influence by ANT2 shRNA-
induced ATP depletion.
Breakdown of the extracellular matrix (ECM) by pro-
teinases is an essential step in cancer invasion and
metastasis [20,21]. Matrix metalloproteinases (MMPs)
are a family of ECM degrading proteinases. Owing to
their matrix-degrading abilities and high expression in
advanced tumors, MMPs were originally implicated in
cancer progression, invasion, and metastasis. They are
produced by a variety of cells. Production of MMP1,
MMP2, MMP9, and MT1-MMP in endothelial cells
has been described [22-27]. Of the four known mem-
brane type matrix metalloproteinases, MT1-MMP is
most often overexpressed one in cancer and is fre-
quently detected in association with the activated form
of MMP2. Moreover, PI3K/Akt activation contributes
to tumor cell invasion through induction of MTI-
MMP; selective targeting of the PI3K/Akt signaling
pathway significantly blocks the invasive potential of
cancer cells [28].
W ea s s u m e dt h a tA T Pd e p l e t i o nb yA N T 2s h R N A
might suppress HSP90 activity, thereby down-regulating
HER2/neu expression and inhibiting the PI3K/Akt sig-
naling pathway, which might be resulted in down-regu-
lation of MMPs expression and subsequent inhibition of
migration and invasion of breast cancer cells. Therefore,
the purpose of our study was to determine whether or
not ANT2 shRNA-mediated HER2/neu inhibition
decreased breast cancer cell invasiveness, and to investi-
gate the potential of ANT2 shRNA for future use as a
therapeutic agent targeting metastasis of human breast
cancer.
Methods
Cell lines and culture
The SK-BR3 human breast cancer cell line was used
throughout the study. These cells were purchased from
the ATCC (Manassas, VA) and cultured in DMEM
(Dulbecco’s Modified Eagle Medium) supplemented
with 10% FBS (fetal calf serum), 100 units/mL penicillin,
and 100 μg/mL streptomycin (Gibco, Grand Island, NY)
in a humidified 5% CO2 /95% air atmosphere at 37°C.
Antibodies and reagents
Anti-human HER2/neu, ubiquitin, and a-tublin antibo-
dies were purchased from Santa Cruz biotechnology
(Heidelberg, Germany). Anti-Akt, anti-phospho-Akt, and
anti-b-actin were purchased from Cell signaling Tech
(Beverly, MA). Anti-MT1-MMP antibodies were pur-
chased from Millipore (Billerica. MA). HSP90 inhibitor,
17-AAG (17-allylamino-17-demethoxygeldanamycin)
was purchased from A.G. Scientific, Inc (San Diego,
CA), and PI3K inhibitor, LY294002 was purchased from
Calbiochem (San Diego, CA).
Transfection
For transfection, cells were plated on either six-well
plates (2 × 10
5 cells per well) or 100 mm dishes (2 ×
10
6 cells) and were allowed to adhere for 24 hours.
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) was used
for the transfection. Cells were transfected with either
pSilencer™ 3.1-H1 puro ANT2 siRNA vectors or pSilen-
cer™ 3.1-H1 puro scramble siRNA vectors (shRNAs).
Transfected cells were then cultured for 6 hours; culture
media were replaced with fresh media supplemented
with 10% FBS. The cells were harvested at 24 - 48 hours
after transfection. pcDNA, pcDNA-ANT2, or wild-type
PI3K/p110 vectors (kindly provided by Dr. Karin Reif)
were transfected into the cells using the same method.
Immunoprecipitations
The cells were collected and lysed for 30 minutes on ice
in 1 mL of a lysis buffer [20 mmol/L Tris (pH 7.5), 150
mmol/L NaCl, 10% (v/v) glycerol, 1% (v/v) Triton X-
100, and 2 mmol/L EDTA] with protease inhibitor cock-
tail (Roche). After removing cell debris by centrifuging
at 15,000 g for 15 minutes at 4°C, the cell lysates (800
μl, 15 mg protein) were precipitated with 80 μlo f
EZview Red anti-Flag M2 Affinity Gel (Sigma) overnight
at 4°C. The complexes were subsequently washed five
times with TBS buffer [50 mmol/L Tris, 150 mmol/L
NaCl (pH 7.4)], suspended in 20 μl of 2× SDS sample
buffer [125 mmol/L (pH 6.8), 10% (w/v) SDS, 20% (v/v)
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and subjected to SDS-PAGE and Western blotting.
Western blotting
For western blot analyses, cells were harvested after 24
or 48 hours of transfection and lysed with lysis buffer
(5 mM/L ethylenediamine tetra acetic acid; 300 mM/L
NaCl; 0.1% NP-40; 0.5 mM/L NaF; 0.5 mM/L Na3VO4;
0.5 mM/L phenylmethylsulfonyl fluoride; and 10 μg/ml
each of aprotinin, pepstatin, and leupeptin; Sigma,
St Louis, MO). Following centrifugation at 15,000 g for
30 minutes, the concentrations of supernatant proteins
were analyzed using the Bradford reagent (Bio-Rad, Her-
cules, CA). For analysis of protein contents, 50 μgo f
total proteins was electrophoresed in 10% SDS-PAGE
gel, and transferred to polyvinylidene difluoride mem-
branes (Millipore, Bedford, MA), which were then incu-
bated with the respective antibodies indicated above.
Immunoblots were visualized using an enhanced chemi-
luminescence detection system (Amersham Pharmacia
Biotech, Uppsala, Sweden).
Reverse transcription-polymerase chain reaction (RT-PCR)
Cells were collected after 24 hours of transfection. Total
RNA was extracted using Trizol (Invitrogen), according to
the manufacturer’s instructions. For RT-PCR analysis, 5 μg
total RNA was reverse-transcribed using RT-PCR kits (Pro-
mega, Madison, WI). PCR was used for amplification of
target cDNA under the following conditions: 35 cycles of
94°C for 1 minute, 55°C for 1 minute, and 72°C for 2 min-
utes. PCR products were analyzed using standard agarose
gel electrophoresis. The primer sequences were used as fol-
l o w s :f o rV E G F ,f o r w a r d5 ′ CTACCTCCACCATGC-
CAAGT 3′ and reverse 5′ GCAGTAGCTGCGCTGCG
CTGATAGA 3′; for MT1-MMP, forward 5′ CCATTGGG-
CATCCAGAAGAGAGC 3′ and reverse 5′ GGATACC-
CAATGCCCATTGGCCA 3′;f o rM M P 9 ,f o r w a r d5 ′ TT
CATCTTCCAAGGCCAATC 3′ and reverse 5′ CTTG
TCGCTGTCAAAGTTCG 3′;f o rM M P 2 ,f o r w a r d5 ′
GGCTGGTCAGTGGCTTGGGGTA 3′ and reverse 5′
AGATCTTCTTCTTCAAGGACCGGTT 3′;a n df o r
GAPDH: forward 5′ ACCACAGTCCATGCCATCAC 3′
and reverse 5′ TCCACCACCCTGTTGCTGT 3′.
Fluorescence-activated cell sorter analysis (intracellular
and surface staining)
pSilencer™ 3.1-H1 puro ANT2 siRNA vectors as well as
pSilencer™ 3.1-H1 puro scramble siRNA vectors were
transfected into SK-BR3 cells for the indicated times.
Six hours before harvesting, the cells were treated with
brefeldin A (10 μg/ml), washed twice with PBS, fixed
with 2% paraformaldehyde, and permeabilized with buf-
fer (1% BSA, 0.1% saponine, 0.1% sodium azide in PBS),
followed by staining with phenylethylene-conjugated
anti-VEGF as well as anti-mouse IgG antibodies (BD
Pharmingen, San Diego, CA) for 1 hour at 4°C and ana-
lysis by flow cytometry (Epics XL; Coulter).
Gelatin zymography
Conditioned medium and cell lysates were electrophor-
esed in a polyacrylamide gel containing 1 mg/ml of gela-
tin. As previously described, proteolysis was detected as
a white zone in a dark blue field [29].
Invasion and migration assays
Matrigel invasion assays were performed using modified
Boyden chambers with polycarbonate Nucleopore mem-
branes (Corning, Corning, NY). Precoated filters (6.5
mm in diameter, 8 μm pore size, Matrigel 100 μg/cm
2)
were rehydrated with 100 μLm e d i u m ;2×1 0
5 cells in
200 μL serum-free DMEM supplemented with 0.1%
bovine serum albumin were seeded into the upper part
of each chamber. Following incubation for 18 hours at
37°C, noninvaded cells on the upper surface of the filter
were wiped out with a cotton swab; and the invaded
cells on the lower surface of the filter were fixed and
stained using a Diff-Quick kit (Fisher Scientific, Pitts-
burgh, PA). Invasiveness was determined by counting
cells in five microscopic fields per well, and the extent
of invasion was expressed as average number of cells
per microscopic field. Transwell migration assays were
performed using the same procedure as that used in
performance of the invasion assay, except that underside
filters with type I collagen was coated.
Results
ANT2 shRNA induces dissociation of HER2/neu from
HSP90, followed by proteasomal degradation of HER2/
neu in breast cancer cells
We first examined regulation of HER2/neu by ANT2
shRNA in HER2/neu-overexpressing breast cancer cell
lines, SK-BR3. As shown Fig. 1A, HER2/neu was down-
regulated by ANT2 shRNA transfection for 24 hours. At
that time, ANT2 shRNA had little influence on the cell
viability by MTT assay, although the morphology of
cells seemed not to be the best under microscopic
examination. Co-immunoprecipitation of HSP90 and
HER2/neu revealed that knockdown of ANT2 by
shRNA resulted in effective dissociation of HER2/neu
from HSP90, and concomitant increased poly-ubiquiti-
nation and degradation of HER2/neu protein (Fig. 1B
and 1C). We used HSP90 inhibitor, 17-AAG, as a posi-
tive control, and the levels of ANT2 shRNA-mediated
dissociation from HSP90 and down-regulation of HER2/
neu protein were nearly comparable to those observed
in 17-AAG-treated cells. To address the mechanism to
inhibit HSP90 activity, we measured the ATP level in
ANT2 shRNA-transfected cells. As observed in other
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shRNA resulted in decrease of ATP levels in SK-BR3
cells (data not shown). These data suggested that ANT2
shRNA decreased HER2/neu protein levels by promot-
ing degradation of HER2/neu protein as a result of dis-
sociation from HSP90.
ANT2 shRNA inhibits the PI3K/Akt signaling pathway in
HER2/neu-overexpressing breast cancer cells
HER2/neu-overexpressing breast cancer cells have been
shown to make increased use of the signaling pathway
mediated by PI3K/Akt. Activated Akt is considered the
focal point of a survival pathway known to protect cells
from apoptosis by several stimuli. Moreover, PI3K could
be involved in regulation of MMP2 and MT1-MMP in
response to cytoskeletal remodeling and induction of
the potent angiogenic factor, VEGF. We next examined
Akt phosphorylation in response to ANT2 shRNA.
Notably, a dramatic decrease in Akt phosphorylation
was detected in SK-BR3 cells transfected with ANT2
shRNA for 24 hours, whereas ANT2 over-expression by
pcDNA vector increased Akt phosphorylation (Fig. 2A
and 2B). It is well known that Akt is also a client pro-
tein of HSP90. Therefore, to investigate if the decreased
Akt activity (phosphorylation) observed in ANT2
shRNA-treated SK-BR3 cells at 24 hours might be a
result from a direct suppression of Akt level, we exam-
ined the effects of inhibition of HSP90 by ANT2 shRNA
on the level of Akt protein. As shown in Fig. 2C,
although ANT2 shRNA led to dissociation of Akt from
HSP90 after 48 hours of transfection, Akt protein was
Figure 1 Down-regulation of HER2/neu by ANT2 shRNA in
HER2/neu overexpressing breast cancer cell lines (SK-BR3). (A)
After 24 hours of transfection with scramble shRNA or ANT2 shRNA,
expression levels of HER2/neu were analyzed using flow cytometry.
(B) For identification of dissociation and degradation of HSP90 from
HER2/neu by ANT2 shRNA, cells were transfected with ANT2 shRNA
for 24 hours and the cellular extracts were prepared for immuno-
precipitation with anti-Her2/neu antibody and subjected to western
blotting with anti-HSP90 and anti-ubiquitin antibodies. HSP90
inhibitor, 17-AAG was used as a positive control. (C) After 24 hours
of transfection with ANT2 shRNA, cells extracts were prepared for
western blotting with anti-Her2/neu and anti-b-actin antibodies.
Figure 2 Down-regulation of Akt activity by ANT2 shRNA in
SK-BR3 cells. (A) After 24 hours of transfection with ANT2 shRNA in
SK-BR3, cells extracts were prepared for western blotting with anti-
phospho Akt and anti-Akt antibodies. 17-AAG was used as a positive
control. (B) To investigate if ANT2 plays a role in the regulation of
Akt activity (phophorylated Akt level) in SK-BR3, cells were
transfected with scramble shRNA, ANT2 shRNA, pcDNA, or pcDNA-
ANT2 and cultured for 24 hours, then cells extracts were prepared
for western blotting with anti-phospho Akt and anti-Akt antibodies.
PI3K inhibitor, LY294002 was used as a positive control to inhibit
PI3K/Akt signaling pathway. (C) To evaluate the effect of ANT2
shRNA-mediated HSP90 suppression on the stability and
phosphorylation of Akt, cells were transfected with ANT2 shRNA for
24 or 48 hours and the cellular extracts were prepared for immuno-
precipitation with anti-HSP90 antibody and subjected to western
blotting with anti-phospho-Akt and anti-Akt antibodies.
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tion in contrast to the marked decrease of Akt phos-
phorylation. Taken together, these findings suggested
that an inhibitory effect of ANT2 shRNA on the PI3K/
Akt signaling pathway in HER2/neu-overexpressing
breast cancer cells (SK-BR3) might be mediated
by degradation of HER2/neu protein rather than Akt
down-regulation, especially in the early time of
transfection.
ANT2 shRNA suppresses VEGF expression, probably
through inhibition of PI3K/Akt signaling pathway
Here, we examined whether ANT2 knockdown by
shRNA affected expression of VEGF, and whether this
might be regulated by the PI3K/Akt signaling pathway.
In cancer progression, PI3K/Akt and NF-Bs i g n a l i n g
pathways are strongly associated with growth, migration,
invasion, angiogenesis, and metastasis of tumor. PI3K
plays a central role in a diverse range of cellular
responses, including cell growth and survival. Akt (also
named protein kinase B) is a downstream target of PI3K
and is also a critical mediator of survival signals for pro-
tection of cells from apoptosis. VEGF, induces modifica-
tion of the actin cytoskeleton and influences endothelial
cell permeability and migration during angiogenesis.
Here, we examined the question of whether or not ANT2
knockdown by shRNA affected on the VEGF expression,
and if which might be regulated by PI3K/Akt signaling
pathway. ANT2 shRNA transfection markedly decreased
VEGF mRNA level, and these changes occurred in con-
cert with changes in VEGF protein levels (Fig. 3A). As
expected, suppression of VEGF expression by ANT2
shRNA seemed to be dependent on ANT2 shRNA-
induced inhibition of PI3K/Akt signaling, considering
that PI3K inhibitor, LY294002, dramatically down-regu-
lated VEGF expression in SK-BR3 cells (Fig. 3B).
ANT2 shRNA down-regulates MT1-MMP and inhibits
expression and activity of MMP2 and MMP9 by inhibiting
PI3K/Akt signaling pathway
A decrease in VEGF protein suggested a concurrent
decrease in MT1-MMP protein, because MT1-MMP has
previously been known as a downstream target of
VEGF. In the present study, we found that MT1-MMP
was significantly decreased in ANT2 shRNA transfected
SK-BR3 cells in both mRNA and protein levels (Fig.
4A). Furthermore, this inhibition of MT1-MMP by
ANT2 shRNA was interrupted and the expression of
MT1-MMP was restored by wild-type PI3K overexpres-
sion (Fig. 4B). These results suggested that inhibition of
PI3K/Akt signaling by ANT2 shRNA might play an
important role in the down-regulation of MT1-MMP
Transfection with ANT2 shRNA was found to signifi-
cantly decrease expression of both MMP2 and MMP9
( F i g .5 A ) .T od e t e r m i n ew h e t h e ro rn o ta c t i v i t yo f
MMP2 and MMP9 is also inhibited by ANT2 shRNA,
gelatin zymography analysis was performed, which
showed that activation of pro-matrix MMP2 and pro-
matrix MMP9 was markedly suppressed in the superna-
tants of SK-BR3 cells transfected by ANT2 shRNA (Fig.
5B). These findings suggested that ANT2 shRNA sup-
pressed MMP2 and MMP9 expression and activity in
HER2/neu-overexpressing breast cancer cells.
ANT2 shRNA suppresses invasiveness and migration of
HER2/neu-overexpressing breast cancer cells
Based on the above observation, we finally studied the
effects of ANT2 shRNA on invasion and migration of
breast cancer cells. In vitro matrigel invasion assay and
transwell migration assay showed that ANT2 shRNA
significantly suppressed the invasion and migration of
SK-BR3 cells after 24 hours of transfection (Fig. 6). At
that time, ANT2 shRNA had little influence on the cell
viability by MTT assay, although the morphology
Figure 3 ANT2 shRNA down-regulates VEGF expression, which
is dependent on the PI3K signaling pathway. (A) Cells were
transfected with scramble shRNA or ANT2 shRNA and cultured for
24 hours. Total RNA was extracted from respective cell lines and
subjected to RT-PCR using specific primers for human VEGF or
GAPDH (internal control). Intracellular levels of VEGF were also
detected by flow cytometry. (B) Cells were pre-treated with PI3K
inhibitor, LY294002. After 2 hours of incubation, cells were
transfected with scramble shRNA, ANT2 shRNA, pcDNA, or pcDNA-
ANT2 and cultured for 24 hours. Total RNA was extracted from
respective cell lines and subjected to RT-PCR using specific primers
for human VEGF or GAPDH (internal control).
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examination. We counted cells numbers in 10-indepen-
det fields (5 mm × 5 mm) and averaged. These data
altogether indicated that invasion (about 65% reduction)
and migration (about 48% reduction) of breast cancer
cells was suppressed or slowed by knockdown of ANT2
probably via inhibition of MMP2 and MMP9 expression
and activity.
Discussion
Abnormal growth and metastasis of cancer cells are
regarded as important biological characteristics of can-
cer development and progression. Metastasis is the main
cause of morbidity and mortality in millions of patients
with cancer. During the complicated process of metasta-
sis, invasion of cancer cells is the most important and
characteristic step. Clearly, an agent with the capacity
for efficient inhibition of growth, migration, and inva-
sion of cancer cells would be a hopeful candidate for
use in suppression of cancer metastasis and progression,
thus resulting in reduced mortality [30].
Among four isoforms of human ANT, ANT2 is speci-
fically expressed in undifferentiated cells or tissues cap-
able of proliferating and regenerating such as
lymphocytes, kidney and liver. In addition, ANT2
expression is known to be up-regulated in several hor-
mone-dependent cancers including breast and ovary
cancer [31]. The overexpression of ANT2 in cancer cells
was found to be associated with glycolytic metabolism
of cancer cells, which raised a possible role of ANT2
during carcinogenesis [32]. In fact, we and others have
shown that ANT2 knockdown decreased cell viability
and induced apoptotic death in breast cancer cells with
Figure 4 ANT2 shRNA down-regulates MT1-MMP expression by
suppressing PI3K signaling in SK-BR3 cells (A). Cells were
transfected with scramble shRNA or ANT2 shRNA. After 24 hours of
incubation, total RNA and cell extracts were prepared for RT-PCR
using specific primers for human MT1-MMP or GAPDH (internal
control) and western blotting with anti-MT1-MMP and anti-b-actin
antibodies. (B) Cells were transfected with scramble shRNA or ANT2
shRNA with or without the wild-type PI3K expression vector and
cultured for 24 hours. After 24 hours of incubation, total RNA and
cell extracts were prepared for RT-PCR using specific primers for
human MT1-MMP or GAPDH (internal control) and western blotting
with anti-MT1-MMP and anti-b-actin antibodies.
Figure 5 ANT2 shRNA down-regulates MMP2 and MMP9
expression and activity in SK-BR3 cells. (A) Cells were transfected
with scramble shRNA or ANT2 shRNA and cultured for 24 hours.
Total RNA was extracted from respective cell lines and subjected to
RT-PCR using specific primers for human MMP2, MMP9, or GAPDH
(internal control). (B) Cells were transfected with scramble shRNA or
ANT2 shRNA and cultured in conditioned medium for 24 hours.
Conditioned medium and cell lysates were electrophoresed in a
polyacrylamide gel containing 1 mg/ml of gelatin. Proteolysis was
detected as a white zone in a dark blue field. Band at 92 kDa
indicates the active MMP9, 72 kDa the inactive MMP2, and 62 kDa
active MMP2.
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lines, and also can sensitize cancer cells to a kind of
chemotherapeutic agents [31,33].
In the work shown here, knockdown of ANT2 by
shRNA inhibited migration and invasion of HER2/neu-
overexpressing breast cancer cell lines (SK-BR3). We
previously reported that ANT2 shRNA induces apopto-
tic cell death in both MCF-7 and MDA-MB-231 cells
[34], which cell lines express basal levels of HER2/neu.
Here, we further showed that ANT2 shRNA also regu-
lates migration and invasion in HER2/neu-overexpres-
sing SK-BR3 cells. Although ANT2 knockdown in SK-
BR3 cells ultimately induced cell death, its suppressing
effect on the cell migration and invasion was observed
much earlier after ANT2 shRNA transfection, which
further emphasizes the potential of ANT2 shRNA to
control breast cancer metastasis. We also observed that
ANT2 shRNA suppresses the migration and invasion of
MCF-7 and MDA-MB-231 cells expressing basal levels
of HER2/neu (data not shown).
We demonstrated here for the first time that ANT2
shRNA induces suppression of cell migration and inva-
sion, accompanied by down-regulation of HER2/neu
through inhibition of HSP90’sf u n c t i o ni nH E R 2 / neu-
overexpressing breast cancer cell lines. Recent studies
have reported on enhanced intracellular degradation of
HER2/neu, which involved targeting HSP90 by benzo-
quinone ansamycins, such as geldanamycin. HSP90
forms complexes with HER2/neu and other client pro-
teins. Once geldanamycin has competitively blocked
ATP binding to HSP90, the chaperone complex asso-
ciated with the client protein is biased toward a degra-
dative fate, resulting in poly-ubiquitination and
subsequent destruction of the client. The mature HER2/
neu requires association ofH S P 9 0w i t hi t sk i n a s e
domain to maintain the conformation necessary for het-
erodimerization with other ligand-activated ErbB pro-
teins [35]. In the present study, ANT2 shRNA
dissociated the complex of HER2/neu and HSP90 and
preceded depletion of HER2/neu. We thus hypothesized
that ANT2 shRNA may also disrupt association of the
HER2/neu and HSP90 complex through depletion of
ATP, which may explain why ANT2 shRNA can deplete
HER2/neu protein. Findings from our present study
show that ANT2 shRNA-induced degradation of mature
HER2/neu involves poly-ubiquitination of HER2/neu
and subsequent hydrolysis by the proteasome.
Here we have shown that ANT2 shRNA-induced
degradation of HER2/neu led to loss of its activation
with PI3K, and a rapid decline in Akt activity in HER2/
neu-overexpressing breast cancer cell lines. The PI3K/
Akt pathway is known to be important in cell survival,
growth, migration, and invasion. This pathway is a pos-
sible target for cancer therapy [36-38]. Findings from
studies with HER2/neu-overexpressing breast cancer cell
lines have demonstrated constitutive phosphorylation of
HER2/neu and highly phosphorylated Akt [39]. Activa-
tion of HER2-containing heterodimers results in recep-
tor autophosphorylation on COOH-terminal tyrosine
residues, which become docking sites for a number of
signal transducers and adaptor molecules that initiate a
plethora of signaling programs leading to cell prolifera-
t i o n ,d i f f e r e n t i a t i o n ,m i g r a t i o n ,a d h e s i o n ,p r o t e c t i o n
from apoptosis, and transformation, among other effects.
PI3K and Akt kinases operate downstream of EGFR and
HER2 in cancer cells, transmitting signals that regulate
cell survival and cell migration [40]. EGFR- and/or
HER2-triggered PI3K/Akt activation may be involved in
regulation of the malignant and metastatic potential.
Therefore, these molecules could serve as targets for
metastases of breast cancer. It would be possible that
ANT2 shRNA-mediate inhibition of HSP90’s activity
ultimately result in Akt depletion and subsequent sup-
pression of Akt activity. However, time kinetics of the
Figure 6 ANT2 shRNA suppresses invasiveness and migration
of SK-BR3 cells in vitro. (A) To evaluate the inhibitory effect of
ANT2 shRNA on invasion and migration of SK-BR3 cells, cells were
transfected with scramble shRNA or ANT2 shRNA and cultured for
24 hours. Matrigel invasion assays were performed using modified
Boyden chambers with polycarbonate Nucleopore membranes.
Following incubation for 18 hours at 37°C, noninvaded cells on the
upper surface of the filter were wiped out with a cotton swab, and
the invaded cells on the lower surface of the filter were fixed and
stained with Diff-Quick kit. (B) Transwell migration assays were
performed using the same procedure used for performance of the
invasion assay, except that the underside of filters was coated with
type I collagen. Data were analyzed using the Student’s t test. P <
0.005 was considered statistically significant.
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Page 7 of 9present study revealed that ANT2 shRNA treatment led
to simultaneous down-regulation of HER2 protein and
phospho-Akt levels, which preceded the degradation of
Akt protein. Therefore, we speculate that PI3K/Akt sig-
naling could be efficiently inhibited by ANT2 shRNA in
a HER2-overexpressing breast cancer through HER2
degradation in advance of Akt degradation.
Tumor cell invasion is dependent on finely regulated
extracellular proteolytic activity, which allows penetra-
tion of tumor cells through ECM. Activated phospho-
Akt enhanced expression of MT1-MMP and MMP2 is
associated with cancer invasion and metastasis, as well
as angiogenesis [41]. This study provides evidence that
inactivation of PI3K/Akt signaling pathway by ANT2
shRNA down-regulates MT1-MMP, MMP2, and MMP9
expression and activity as well as VEGF expression in a
HER2/neu-overexpressing breast cancer cell line.
Conclusions
In conclusion, the results of this study provide mechan-
istic evidence that ANT2 shRNA suppresses induced
migration and invasion by depletion of HER2/neu pro-
tein and, in turn, suppression of HER2/PI3K/Akt path-
way signaling and subsequent suppression of proteolytic
activity by down-regulating MMPs. We propose that
gene therapy using ANT2 shRNA may be a potentially
effective therapeutic tool against HER2/neu-overexpres-
sing breast cancers.
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